vs
Clearwater Paper Corp（CLW）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Clearwater Paper Corp的季度营收约是Ultragenyx Pharmaceutical Inc.的1.7倍（$360.3M vs $207.3M），Clearwater Paper Corp净利率更高（-3.6% vs -62.0%，领先58.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -4.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.3%）
净水纸业公司是美国的一家纸浆与纸板制造商，总部位于华盛顿州斯波坎。公司于2008年12月9日从波特拉奇公司分拆设立，专注于纸浆及纸板产品的研发生产与销售，是北美地区该领域颇具影响力的生产企业。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CLW vs RARE — 直观对比
营收规模更大
CLW
是对方的1.7倍
$207.3M
营收增速更快
RARE
高出30.6%
-4.7%
净利率更高
CLW
高出58.5%
-62.0%
两年增速更快
RARE
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $360.3M | $207.3M |
| 净利润 | $-12.8M | $-128.6M |
| 毛利率 | -0.2% | — |
| 营业利润率 | — | -54.7% |
| 净利率 | -3.6% | -62.0% |
| 营收同比 | -4.7% | 25.9% |
| 净利润同比 | -103.2% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLWRARE
| Q1 26 | $360.3M | — | ||
| Q4 25 | $386.4M | $207.3M | ||
| Q3 25 | $399.0M | $159.9M | ||
| Q2 25 | $391.8M | $166.5M | ||
| Q1 25 | $378.2M | $139.3M | ||
| Q4 24 | $387.1M | $164.6M | ||
| Q3 24 | $393.3M | $139.5M | ||
| Q2 24 | $344.4M | $147.0M |
净利润CLWRARE
| Q1 26 | $-12.8M | — | ||
| Q4 25 | $38.3M | $-128.6M | ||
| Q3 25 | $-53.3M | $-180.4M | ||
| Q2 25 | $2.7M | $-115.0M | ||
| Q1 25 | $-6.3M | $-151.1M | ||
| Q4 24 | $199.1M | $-133.2M | ||
| Q3 24 | $5.8M | $-133.5M | ||
| Q2 24 | $-25.8M | $-131.6M |
毛利率CLWRARE
| Q1 26 | -0.2% | — | ||
| Q4 25 | 4.5% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 11.0% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | -0.6% | — |
营业利润率CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | -54.7% | ||
| Q3 25 | -13.9% | -106.9% | ||
| Q2 25 | 2.5% | -64.8% | ||
| Q1 25 | -1.1% | -102.6% | ||
| Q4 24 | -4.0% | -74.3% | ||
| Q3 24 | -0.3% | -94.6% | ||
| Q2 24 | -13.6% | -79.1% |
净利率CLWRARE
| Q1 26 | -3.6% | — | ||
| Q4 25 | 9.9% | -62.0% | ||
| Q3 25 | -13.4% | -112.8% | ||
| Q2 25 | 0.7% | -69.0% | ||
| Q1 25 | -1.7% | -108.5% | ||
| Q4 24 | 51.4% | -80.9% | ||
| Q3 24 | 1.5% | -95.7% | ||
| Q2 24 | -7.5% | -89.5% |
每股收益（稀释后）CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | $2.36 | $-1.28 | ||
| Q3 25 | $-3.30 | $-1.81 | ||
| Q2 25 | $0.17 | $-1.17 | ||
| Q1 25 | $-0.38 | $-1.57 | ||
| Q4 24 | $11.87 | $-1.34 | ||
| Q3 24 | $0.35 | $-1.40 | ||
| Q2 24 | $-1.55 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.5M | $421.0M |
| 总债务越低越好 | $361.1M | — |
| 股东权益账面价值 | $813.8M | $-80.0M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资CLWRARE
| Q1 26 | $36.5M | — | ||
| Q4 25 | $30.7M | $421.0M | ||
| Q3 25 | $34.4M | $202.5M | ||
| Q2 25 | $46.7M | $176.3M | ||
| Q1 25 | $44.0M | $127.1M | ||
| Q4 24 | $79.6M | $174.0M | ||
| Q3 24 | $35.5M | $150.6M | ||
| Q2 24 | $39.6M | $480.7M |
总债务CLWRARE
| Q1 26 | $361.1M | — | ||
| Q4 25 | $346.8M | — | ||
| Q3 25 | $337.0M | — | ||
| Q2 25 | $330.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $283.4M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — |
股东权益CLWRARE
| Q1 26 | $813.8M | — | ||
| Q4 25 | $825.3M | $-80.0M | ||
| Q3 25 | $783.0M | $9.2M | ||
| Q2 25 | $836.8M | $151.3M | ||
| Q1 25 | $836.6M | $144.2M | ||
| Q4 24 | $854.6M | $255.0M | ||
| Q3 24 | $664.6M | $346.8M | ||
| Q2 24 | $658.6M | $432.4M |
总资产CLWRARE
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B |
负债/权益比CLWRARE
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.42× | — | ||
| Q3 25 | 0.43× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 1.73× | — | ||
| Q2 24 | 1.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | $5.0M | $-99.8M | ||
| Q3 25 | $34.0M | $-91.4M | ||
| Q2 25 | $-28.2M | $-108.3M | ||
| Q1 25 | $1.5M | $-166.5M | ||
| Q4 24 | $-35.1M | $-79.3M | ||
| Q3 24 | $16.2M | $-67.0M | ||
| Q2 24 | $21.1M | $-77.0M |
自由现金流CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | $-9.9M | $-100.8M | ||
| Q3 25 | $15.7M | $-92.7M | ||
| Q2 25 | $-51.1M | $-110.7M | ||
| Q1 25 | $-31.2M | $-167.8M | ||
| Q4 24 | $-68.1M | $-79.5M | ||
| Q3 24 | $-30.8M | $-68.6M | ||
| Q2 24 | $3.0M | $-79.0M |
自由现金流率CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | -2.6% | -48.6% | ||
| Q3 25 | 3.9% | -58.0% | ||
| Q2 25 | -13.0% | -66.5% | ||
| Q1 25 | -8.2% | -120.5% | ||
| Q4 24 | -17.6% | -48.3% | ||
| Q3 24 | -7.8% | -49.2% | ||
| Q2 24 | 0.9% | -53.7% |
资本支出强度CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | 3.9% | 0.5% | ||
| Q3 25 | 4.6% | 0.8% | ||
| Q2 25 | 5.8% | 1.5% | ||
| Q1 25 | 8.6% | 1.0% | ||
| Q4 24 | 8.5% | 0.1% | ||
| Q3 24 | 12.0% | 1.2% | ||
| Q2 24 | 5.3% | 1.4% |
现金转化率CLWRARE
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -10.44× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.18× | — | ||
| Q3 24 | 2.79× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLW
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
